NCT03112577View on ClinicalTrials.gov

Study of REGN3500 and Dupilumab in Patients With Asthma

PHASE1CompletedINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

June 15, 2017

Primary Completion Date

March 20, 2019

Study Completion Date

December 9, 2019

Conditions
Asthma, Allergic
Interventions
DRUG

REGN3500

Intravenous (IV) use

DRUG

Dupilumab

Subcutaneous (SC) use

DRUG

Placebo

Matching placebo

DRUG

Fluticasone propionate

Inhalation use

Trial Locations (5)

90630

WCCT Global, Cypress

BT9 6AD

Celerion, Belfast

NW10 7EW

Hammersmith Medicine Research, London

W1G 8HU

Respiratory Clinical Trials Ltd, London

M23 9QZ

The Medicines Evaluation Unit, Manchester

Sponsors

Collaborators (1)

Sanofi
All Listed Sponsors
collaborator

Sanofi

INDUSTRY

lead

Regeneron Pharmaceuticals

INDUSTRY

NCT03112577 - Study of REGN3500 and Dupilumab in Patients With Asthma | Biotech Hunter | Biotech Hunter